25 completed, 19 active not recruiting, 18 recruiting, 17 terminated. 56 Phase 2, 25 Phase 1, 8 Phase 3, 3 Early Phase 1, 2 Phase 4.
Follow encorafenib: new trials by email Literature Review of encorafenib trials Research Report on encorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations Rechalange with bevacizumab + encorafenib - Colo-rectal Cancer | Phase 2 | Not yet recruiting | Vall d'Hebron Institute of Oncology | 25 | 2025-10-01 | 2025-09-17 |
| Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib Encorafenib & Binimetinib Treatment - Melanoma BRAF V600E/K Mutated | Phase 4 | Withdrawn | SRH Wald-Klinikum Gera GmbH | 2025-08-01 | 2026-04-21 | |
| UK ENcorafenib and BInimetinib Real-world Study in Melanoma Encorafenib + Binimetinib - Metastatic Melanoma, BRAF V600 Mutation Positive | Active not recruiting | Pierre Fabre Ltd | 50 | 2025-07-31 | 2026-04-13 | |
| Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases Encorafenib + Binimetinib, cemiplimab+fianlimab - Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases | Phase 2 | Recruiting | Grupo Español Multidisciplinar de Melanoma | 33 | 2025-05-29 | 2025-10-01 |
| Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC Cetuximab, Encorafenib - Colorectal Cancer | Phase 2 | Completed | Gruppo Oncologico del Nord-Ovest | 16 | 2024-07-23 | 2026-10-28 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-06-05 | 2026-10-30 |
| Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms | Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 25 | 2024-06-03 | 2025-02-12 |
| Combination Therapy for BRAF-V600E Metastatic CRCm Encorafenib, Cetuximab, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Vall d'Hebron Institute of Oncology | 94 | 2024-05-17 | 2024-11-08 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy Cetuximab, Ulixertinib, Encorafenib - Metastatic Colorectal Cancer | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 27 | 2024-01-18 | 2026-09-11 |
| Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma Pembrolizumab, Encorafenib, Binimetinib - Malignant Melanoma, Metastatic Melanoma | Phase 2 | Completed | Dr. Ronnie Shapira | 1 | 2023-09-05 | 2025-07-22 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma encorafenib, binimetinib, pembrolizumab - Melanoma | Phase 2 | Terminated | Pfizer | 38 | 2023-06-13 | 2026-03-09 |
| Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma Encorafenib + Binimetinib, Standard Adjuvant Treatment - Melanoma, Cancer | Phase 2 | Active not recruiting | CCTU- Cancer Theme | 18 | 2023-02-27 | 2026-10-26 |
| ZN-c3 in Adult Participants With Metastatic Colorectal Cancer ZN-c3, Encorafenib, Cetuximab - Metastatic Colorectal Cancer | Phase 1 | Terminated | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 44 | 2023-02-27 | 2025-08-08 |
| Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer Encorafenib Oral Capsule + Cetuximab - Colorectal Cancer, BRAF V600E Mutation Positive | Phase 2 | Recruiting | Federation Francophone de Cancerologie Digestive | 30 | 2023-02-13 | 2025-09-02 |
| Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab - Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer | Phase 2 | Terminated | Northwestern University | 7 | 2022-10-10 | 2026-06-12 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
Showing 20 of 87. Sign in to see all of them.
Melanoma (40) · Colorectal Neoplasms (25) · Colonic Neoplasms (10) · Brain Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (7) · Neoplasms (7) · Neoplasm Metastasis (6) · Rectal Neoplasms (5) · Skin Neoplasms (4) · Gastrointestinal Neoplasms (3) · Lung Neoplasms (3) · Digestive System Neoplasms (2) · Pancreatic Neoplasms (2) · Astrocytoma (1) · Biliary Tract Neoplasms (1)
Pfizer (20) · Pierre Fabre Medicament (6) · M.D. Anderson Cancer Center (5) · Array BioPharma (3) · National Cancer Institute (NCI) (3) · Grupo Español Multidisciplinar de Melanoma (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Memorial Sloan Kettering Cancer Center (2) · Peter MacCallum Cancer Centre, Australia (2) · Pierre Fabre Pharma GmbH (2) · UNICANCER (2) · Vall d'Hebron Institute of Oncology (2) · AIO-Studien-gGmbH (1) · Academic and Community Cancer Research United (1) · Alliance for Clinical Trials in Oncology (1)
United States (53) · Spain (25) · Italy (22) · Australia (19) · Germany (19) · France (18) · Canada (15) · Netherlands (15) · United Kingdom (14) · Belgium (13) · Poland (10) · Norway (9) · Switzerland (9) · Czechia (8) · Austria (7)
Array BioPharma (2) · Li Zhang, MD (2) · Van K Morris (2) · Alexander Stein, Prof. Dr. (1) · Alfonso Berrocal Jaime, M.D. (1) · Andrew E Hendifar (1) · Andrew Furness, MBBS, MRCP, PhD (1) · Anna Spreafico, MD (1) · Antoni Ribas (1) · Aparna Parikh, MD (1) · Carlotta Antoniotti, MD, PhD (1)
PMID 34655839, PMID 35385748, PMID 36763936, PMID 19942357, PMID 26112811, PMID 27288470, PMID 28592387, PMID 29573941, PMID 30219628, PMID 30892987, PMID 31437754, PMID 31566309, PMID 31744895, PMID 32669376, PMID 33503393, PMID 34091420, PMID 34376578, PMID 34625515, PMID 34774225, PMID 34918546, PMID 34986285, PMID 35272485, PMID 35653981, PMID 35654691, PMID 35862871, PMID 36049147, PMID 36608320, PMID 36653241, PMID 36653848, PMID 36811382, PMID 37270692, PMID 37309702, PMID 37506329, PMID 37534686, PMID 37665297, PMID 37815847, PMID 38167503, PMID 38424308, PMID 38698170, PMID 38878209, PMID 38900987, PMID 38946469, PMID 39313594, PMID 39315864, PMID 39863775, PMID 40439484, PMID 40444708, PMID 40449497, PMID 40480428, PMID 40578933
2023 (5), 2018 (3), 2014 (2), 2019 (2), U10CA180888 (2), 2015 (1), 2016 (1), 2017 (1), P01CA168585 (1), P30CA015083 (1), P30CA060553 (1), R01CA258751 (1), U10CA180820 (1), UM1CA137443 (1), UM1CA186688 (1)